MRTNZ

MRTNZ Investment Office · S&P 500 · The 360 Vantage

PODD · NASDAQ-GS

Insulet Corporation

Health Care · Medical/Dental Instruments

Reference price$167.47As of Jul 28, 2026
Market capitalization$11.6B
52-week range$138.79–$354.88
S&P 500 portfolio weight0.02%
Data qualitycomplete

Street view

Analyst targets

Published sell-side aggregation—not an MRTNZ forecast.

Low$172.00+2.7% vs. reference
Average$221.38+32.2% vs. reference
High$294.00+75.6% vs. reference
17 Buy3 Hold1 Sell

Forward calendar

Current earnings expectations

Consensus may change until the company reports.

Expected reportAug 5, 2026Jun 2026
Consensus EPS$1.388 estimates
Expected range$0.97–$1.50Low to high EPS
Dec 2026$6.45Street EPS consensus
Dec 2027$7.99Street EPS consensus
Dec 2028$10.00Street EPS consensus

Reported results

Annual financial snapshot

Fiscal period ended Dec 31, 2025.

MetricCurrentPrior
Revenue+30.7% YoY$2.71B$2.07B
Operating income$0.47B$0.31B
Net income$0.25B$0.42B
Operating cash flow$0.57B$0.43B
Capital expenditures($0.19B)($0.12B)

Current context

Related news

Company-linked articles surfaced by Nasdaq.

Zacks

Here's How Much You'd Have If You Invested $1000 in Insulet a Decade Ago

Zacks

Insulet Broadens Omnipod 5 Presence With Commercial Launch in Spain

Zacks

Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?

Evidence

Sources & method

Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official S&P 500-tracking holdings →

Facts, estimates, and scenarios are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Index weight uses the official IVV portfolio as the denominator. Illustrative research, not investment advice.